Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 16 October 1998:
Vol. 282. no. 5388, pp. 490 - 493
DOI: 10.1126/science.282.5388.490
Prev | Table of Contents | Next

Reports

Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin

Isabelle Viard, Philippe Wehrli, * Roberto Bullani, * Pascal Schneider, Nils Holler, Denis Salomon, Thomas Hunziker, Jean-Hilaire Saurat, Jürg Tschopp, Lars E. French dagger

Toxic epidermal necrolysis (TEN, Lyell's syndrome) is a severe adverse drug reaction in which keratinocytes die and large sections of epidermis separate from the dermis. Keratinocytes normally express the death receptor Fas (CD95); those from TEN patients were found to express lytically active Fas ligand (FasL). Antibodies present in pooled human intravenous immunoglobulins (IVIG) blocked Fas-mediated keratinocyte death in vitro. In a pilot study, 10 consecutive individuals with clinically and histologically confirmed TEN were treated with IVIG; disease progression was rapidly reversed and the outcome was favorable in all cases. Thus, Fas-FasL interactions are directly involved in the epidermal necrolysis of TEN, and IVIG may be an effective treatment.

I. Viard, P. Wehrli, R. Bullani, D. Salomon, J.-H. Saurat, L. E. French, Department of Dermatology, Geneva University Medical School, CH-1211 Geneva 4, Switzerland. P. Schneider, N. Holler, J. Tschopp, Institute of Biochemistry, University of Lausanne, BIL Research Center, Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland. T. Hunziker, Department of Dermatology, University of Bern, Medical School, CH-3010 Bern, Switzerland.
*   These authors contributed equally to this work.

dagger    To whom correspondence should be addressed. E-mail: french{at}cmu.unige.ch

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.
J. Borras-Blasco, A. Navarro-Ruiz, C. Borras, and E. Castera (2008)
J. Antimicrob. Chemother.
   Abstract »    Full Text »    PDF »
Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome.
M Ueta, C Sotozono, T Inatomi, K Kojima, J Hamuro, and S Kinoshita (2008)
Br. J. Ophthalmol. 92, 989-991
   Abstract »    Full Text »    PDF »
Efficacy of plasmapheresis in the treatment of refractory toxic epidermal necrolysis-like acute cutaneous lupus erythematosus.
I Simsek, M Cinar, H Erdem, S Pay, C Meric, and A Dinc (2008)
Lupus 17, 605-606
   PDF »
Lamotrigine-Induced Toxic Epidermal Necrolysis Treated With Intravenous Immunoglobulin and Amniotic Membranes.
R. Schwartz, E. Avello, and F. Palisson (2008)
Arch Dermatol 144, 724-726
   Full Text »    PDF »
IL-18 is a key proximal mediator of contact hypersensitivity and allergen-induced Langerhans cell migration in murine epidermis.
C. Antonopoulos, M. Cumberbatch, J. B. Mee, R. J. Dearman, X.-Q. Wei, F. Y. Liew, I. Kimber, and R. W. Groves (2008)
J. Leukoc. Biol. 83, 361-367
   Abstract »    Full Text »    PDF »
Management of toxic epidermal necrolysis and related syndromes.
Y Mukasa and N Craven (2008)
Postgrad. Med. J. 84, 60-65
   Abstract »    Full Text »    PDF »
Fas Ligand-induced Proinflammatory Transcriptional Responses in Reconstructed Human Epidermis: RECRUITMENT OF THE EPIDERMAL GROWTH FACTOR RECEPTOR AND ACTIVATION OF MAP KINASES.
S. M. Farley, D. E. Purdy, O. P. Ryabinina, P. Schneider, B. E. Magun, and M. S. Iordanov (2008)
J. Biol. Chem. 283, 919-928
   Abstract »    Full Text »    PDF »
Intravenous Immunoglobulins in Autoimmune and Inflammatory Diseases: A Mechanistic Perspective.
S. SIBERIL, S. ELLURU, S. GRAFF-DUBOIS, V.-S. NEGI, S. DELIGNAT, L. MOUTHON, S. LACROIX-DESMAZES, M. D. KAZATCHKINE, J. BAYARY, and S. V. KAVERI (2007)
Ann. N.Y. Acad. Sci. 1110, 497-506
   Abstract »    Full Text »    PDF »
Intravenous Immunoglobulin and Autoimmune Disease.
T. EL-SHANAWANY and S. JOLLES (2007)
Ann. N.Y. Acad. Sci. 1110, 507-515
   Abstract »    Full Text »    PDF »
Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome.
M. Ueta, C. Sotozono, T. Inatomi, K. Kojima, K. Tashiro, J. Hamuro, and S. Kinoshita (2007)
Br. J. Ophthalmol. 91, 962-965
   Abstract »    Full Text »    PDF »
The antiinflammatory activity of IgG: the intravenous IgG paradox.
F. Nimmerjahn and J. V. Ravetch (2007)
J. Exp. Med. 204, 11-15
   Abstract »    Full Text »    PDF »
FasL and TRAIL Induce Epidermal Apoptosis and Skin Ulceration Upon Exposure to Leishmania major.
L. Eidsmo, C. Fluur, B. Rethi, S. Eriksson Ygberg, N. Ruffin, A. De Milito, H. Akuffo, and F. Chiodi (2007)
Am. J. Pathol. 170, 227-239
   Abstract »    Full Text »    PDF »
Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations.
S. von Gunten, A. Schaub, M. Vogel, B. M. Stadler, S. Miescher, and H.-U. Simon (2006)
Blood 108, 4255-4259
   Abstract »    Full Text »    PDF »
Picture of the Month--Diagnosis.
(2006)
Arch Pediatr Adolesc Med 160, 802
   Full Text »    PDF »
Treatment of Severe Adverse Cutaneous Drug Reactions With Human Intravenous Immunoglobulin in Two Dogs.
T. K. Trotman, H. Phillips, H. Fordyce, L. G. King, D. O. Morris, and U. Giger (2006)
J. Am. Anim. Hosp. Assoc. 42, 312-320
   Abstract »    Full Text »    PDF »
Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy.
G. Curigliano, V. Formica, T. De Pas, G. Spitaleri, E. Pietri, N. Fazio, F. de Braud, and A. Goldhirsch (2006)
Ann. Onc. 17, 1174-1175
   Full Text »    PDF »
Phosphatidylinositol 3-Kinase/Akt Positively Regulates Fas (CD95)-Mediated Apoptosis in Epidermal Cl41 Cells..
B. Lu, L. Wang, C. Stehlik, D. Medan, C. Huang, S. Hu, F. Chen, X. Shi, and Y. Rojanasakul (2006)
J. Immunol. 176, 6785-6793
   Abstract »    Full Text »    PDF »
Colonic involvement in Stevens-Johnson syndrome..
N Powell, J M Munro, and D Rowbotham (2006)
Postgrad. Med. J. 82, e10
   Abstract »    Full Text »    PDF »
Treatment of Anticonvulsant Hypersensitivity Syndrome with Intravenous Immunoglobulins and Corticosteroids.
D. Prais, R. Straussberg, J. Amir, M. Nussinovitch, and L. Harel (2006)
J Child Neurol 21, 380-384
   Abstract »    PDF »
Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature..
G. Vecchietti, K. Kerl, C. Prins, G. Kaya, J.-H. Saurat, and L. E. French (2006)
Arch Dermatol 142, 213-217
   Abstract »    Full Text »    PDF »
Novel Mechanisms of Target Cell Death and Survival and of Therapeutic Action of IVIg in Pemphigus.
J. Arredondo, A. I. Chernyavsky, A. Karaouni, and S. A. Grando (2005)
Am. J. Pathol. 167, 1531-1544
   Abstract »    Full Text »    PDF »
Myocardial Infarction Associated with Intravenous Immune Globulin.
S. B. Stenton, D. Dalen, and K. Wilbur (2005)
Ann. Pharmacother. 39, 2114-2118
   Abstract »    Full Text »    PDF »
Case 34-2005 -- A 10-Year-Old Girl with a Bullous Skin Eruption and Acute Respiratory Failure..
R. L. Sheridan, V. Liu, and S. Anupindi (2005)
N. Engl. J. Med. 353, 2057-2066
   Full Text »    PDF »
Clinical and investigational considerations for the use of IGIV therapy.
M. Ballow (2005)
Am. J. Health Syst. Pharm. 62, S12-S18
   Abstract »    Full Text »    PDF »
Comparative Analysis of Antigen Specificities in the Monomeric and Dimeric Fractions of Intravenous Immunoglobulin.
S. M. MIESCHER, A. SCHAUB, M. GHIELMETTI, M. BAUMANN, M. VOGEL, R. BOLLI, and B. STADLER (2005)
Ann. N.Y. Acad. Sci. 1051, 582-590
   Abstract »    Full Text »    PDF »
Immunomodulatory Effects of Intravenous Immunoglobulins as a Treatment for Autoimmune Diseases, Cancer, and Recurrent Pregnancy Loss.
T. SAPIR, M. BLANK, and Y. SHOENFELD (2005)
Ann. N.Y. Acad. Sci. 1051, 743-778
   Abstract »    Full Text »    PDF »
New Approaches and Therapeutics Targeting Apoptosis in Disease.
U. Fischer and K. Schulze-Osthoff (2005)
Pharmacol. Rev. 57, 187-215
   Abstract »    Full Text »    PDF »
Uncovering Histologic Criteria With Prognostic Significance in Toxic Epidermal Necrolysis.
A. M. Quinn, K. Brown, B. K. Bonish, J. Curry, K. B. Gordon, J. Sinacore, R. Gamelli, and B. J. Nickoloff (2005)
Arch Dermatol 141, 683-687
   Abstract »    Full Text »    PDF »
Cell-Mediated Immunologic Mechanism and Severity of TEN.
O. Faye, J. Wechsler, and J.-C. Roujeau (2005)
Arch Dermatol 141, 775-776
   Full Text »    PDF »
cFLIPL Inhibits Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated NF-{kappa}B Activation at the Death-inducing Signaling Complex in Human Keratinocytes.
T. Wachter, M. Sprick, D. Hausmann, A. Kerstan, K. McPherson, G. Stassi, E.-B. Brocker, H. Walczak, and M. Leverkus (2004)
J. Biol. Chem. 279, 52824-52834
   Abstract »    Full Text »    PDF »
Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions.
W Ting, M S Stone, D Racila, R H Scofield, and R D Sontheimer (2004)
Lupus 13, 941-950
   Abstract »    PDF »
Use of SCORTEN to Accurately Predict Mortality in Patients With Toxic Epidermal Necrolysis in the United States.
J. T. Trent, R. S. Kirsner, P. Romanelli, and F. A. Kerdel (2004)
Arch Dermatol 140, 890-892
   Full Text »    PDF »
Aging of Human Epidermis: Reversal of Aging Changes Correlates With Reversal of Keratinocyte Fas Expression and Apoptosis.
A. Gilhar, Y. Ullmann, R. Karry, R. Shalaginov, B. Assy, S. Serafimovich, and R. S. Kalish (2004)
J. Gerontol. A Biol. Sci. Med. Sci. 59, B411-B415
   Abstract »    Full Text »    PDF »
Kinetics and Specificity of Fas Ligand Induction in Toxic Epidermal Necrolysis.
H. Y. Chang, Z. A. Cooper, S. M. Swetter, and M. P. Marinkovich (2004)
Arch Dermatol 140, 242-244
   Full Text »    PDF »
Use of Intravenous Immunoglobulin in Children With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Seven Cases and Review of the Literature.
D. W. Metry, P. Jung, and M. L. Levy (2003)
Pediatrics 112, 1430-1436
   Abstract »    Full Text »    PDF »
Delayed Drug Hypersensitivity Reactions.
W. J. Pichler (2003)
Ann Intern Med 139, 683-693
   Abstract »    Full Text »    PDF »
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools.
R. Greil, G. Anether, K. Johrer, and I. Tinhofer (2003)
J. Leukoc. Biol. 74, 311-330
   Abstract »    Full Text »    PDF »
Scoring With SCORTEN--Reply.
J. T. Trent, R. S. Kirsner, P. Romanelli, and F. A. Kerdel (2003)
Arch Dermatol 139, 1215-1216
   Full Text »    PDF »
Consensus Statement on the Use of Intravenous Immunoglobulin Therapy in the Treatment of Autoimmune Mucocutaneous Blistering Diseases.
A. R. Ahmed and M. V. Dahl (2003)
Arch Dermatol 139, 1051-1059
   Abstract »    Full Text »    PDF »
Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Are Induced by Soluble Fas Ligand.
R. Abe, T. Shimizu, A. Shibaki, H. Nakamura, H. Watanabe, and H. Shimizu (2003)
Am. J. Pathol. 162, 1515-1520
   Abstract »    Full Text »    PDF »
Intracellular Localization of Keratinocyte Fas Ligand Explains Lack of Cytolytic Activity under Physiological Conditions.
I. Viard-Leveugle, R. R. Bullani, P. Meda, O. Micheau, A. Limat, J.-H. Saurat, J. Tschopp, and L. E. French (2003)
J. Biol. Chem. 278, 16183-16188
   Abstract »    Full Text »    PDF »
Expression of Dominant-negative Fas-associated Death Domain Blocks Human Keratinocyte Apoptosis and Vesication Induced by Sulfur Mustard.
D. S. Rosenthal, A. Velena, F.-P. Chou, R. Schlegel, R. Ray, B. Benton, D. Anderson, W. J. Smith, and C. M. Simbulan-Rosenthal (2003)
J. Biol. Chem. 278, 8531-8540
   Abstract »    Full Text »    PDF »
Two Adjacent Trimeric Fas Ligands Are Required for Fas Signaling and Formation of a Death-Inducing Signaling Complex.
N. Holler, A. Tardivel, M. Kovacsovics-Bankowski, S. Hertig, O. Gaide, F. Martinon, A. Tinel, D. Deperthes, S. Calderara, T. Schulthess, et al. (2003)
Mol. Cell. Biol. 23, 1428-1440
   Abstract »    Full Text »    PDF »
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin.
J. Bayry, S. Lacroix-Desmazes, C. Carbonneil, N. Misra, V. Donkova, A. Pashov, A. Chevailler, L. Mouthon, B. Weill, P. Bruneval, et al. (2003)
Blood 101, 758-765
   Abstract »    Full Text »    PDF »
Treatment of Toxic Epidermal Necrolysis With High-Dose Intravenous Immunoglobulins: Multicenter Retrospective Analysis of 48 Consecutive Cases.
C. Prins, F. A. Kerdel, R. S. Padilla, T. Hunziker, S. Chimenti, I. Viard, D. N. Mauri, K. Flynn, J. Trent, D. J. Margolis, et al. (2003)
Arch Dermatol 139, 26-32
   Abstract »    Full Text »    PDF »
Intravenous Immunoglobulin Treatment for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Prospective Noncomparative Study Showing No Benefit on Mortality or Progression.
N. Bachot, J. Revuz, and J.-C. Roujeau (2003)
Arch Dermatol 139, 33-36
   Abstract »    Full Text »    PDF »
Analysis of Intravenous Immunoglobulin for the Treatment of Toxic Epidermal Necrolysis Using SCORTEN: The University of Miami Experience.
J. T. Trent, R. S. Kirsner, P. Romanelli, and F. A. Kerdel (2003)
Arch Dermatol 139, 39-43
   Abstract »    Full Text »    PDF »
Treatment of Toxic Epidermal Necrolysis: The Uncertainty Persists but the Fog Is Dispersing.
K. Wolff and G. Tappeiner (2003)
Arch Dermatol 139, 85-86
   Full Text »    PDF »
Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies.
M. C. Dalakas (2002)
Neurology 59, S13-21
   Abstract »    Full Text »
Recurrent Erythema Multiforme/Stevens-Johnson Syndrome: Response to Mycophenolate Mofetil.
M. D. P. Davis, R. S. Rogers III, and M. R. Pittelkow (2002)
Arch Dermatol 138, 1547-1550
   Full Text »    PDF »
Natural recognition repertoire and the evolutionary emergence of the combinatorial immune system.
J. J. MARCHALONIS, S. KAVERI, S. LACROIX-DESMAZES, and M. D. KAZATCHKINE (2002)
FASEB J 16, 842-848
   Abstract »    Full Text »    PDF »
CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications.
A. Janin, C. Deschaumes, M. Daneshpouy, J. Estaquier, J. Micic-Polianski, P. Rajagopalan-Levasseur, K. Akarid, N. Mounier, E. Gluckman, G. Socie, et al. (2002)
Blood 99, 2940-2947
   Abstract »    Full Text »    PDF »
Intravenous immunoglobulin in neurological disease: a specialist review.
C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al. (2002)
J. Neurol. Neurosurg. Psychiatry 72, 440-448
   Abstract »    Full Text »    PDF »
Soluble Interleukin 2 Receptor and Interleukin 1{alpha} in Toxic Epidermal Necrolysis: A Comparative Analysis of Serum and Blister Fluid Samples.
O. Correia, L. Delgado, J.-C. Roujeau, L. Le Cleach, and J. A. Fleming-Torrinha (2002)
Arch Dermatol 138, 29-32
   Abstract »    Full Text »    PDF »
Treatment of Extensive Toxic Epidermal Necrolysis in Children.
M. Spies, A. P. Sanford, J. F. A. Low, S. E. Wolf, and D. N. Herndon (2001)
Pediatrics 108, 1162-1168
   Abstract »    Full Text »    PDF »
Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin.
M. D. Kazatchkine and S. V. Kaveri (2001)
N. Engl. J. Med. 345, 747-755
   Full Text »    PDF »
Acute Rejection in the Absence of Cognate Recognition of Allograft by T Cells.
M. Y. Braun, I. Grandjean, P. Feunou, L. Duban, R. Kiss, M. Goldman, and O. Lantz (2001)
J. Immunol. 166, 4879-4883
   Abstract »    Full Text »    PDF »
FAS engagement drives apoptosis of enterocytes of coeliac patients.
L Maiuri, C Ciacci, V Raia, L Vacca, I Ricciardelli, F Raimondi, S Auricchio, S Quaratino, and M Londei (2001)
Gut 48, 418-424
   Abstract »    Full Text »    PDF »
The Drug Hypersensitivity Syndrome: What Is the Pathogenesis?.
J. R. Sullivan and N. H. Shear (2001)
Arch Dermatol 137, 357-364
   Full Text »    PDF »
Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor.
A. Samuelsson, T. L. Towers, and J. V. Ravetch (2001)
Science 291, 484-486
   Abstract »    Full Text »
Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure.
L. Gullestad, H. Aass, J. G. Fjeld, L. Wikeby, A. K. Andreassen, H. Ihlen, S. Simonsen, J. Kjekshus, S. Nitter-Hauge, T. Ueland, et al. (2001)
Circulation 103, 220-225
   Abstract »    Full Text »    PDF »
Fas (CD95) Induces Alveolar Epithelial Cell Apoptosis in Vivo : Implications for Acute Pulmonary Inflammation.
G. Matute-Bello, R. K. Winn, M. Jonas, E. Y. Chi, T. R. Martin, and W. C. Liles (2001)
Am. J. Pathol. 158, 153-161
   Abstract »    Full Text »    PDF »
Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft.
P. Tiberghien, C. Ferrand, B. Lioure, N. Milpied, R. Angonin, E. Deconinck, J.-M. Certoux, E. Robinet, P. Saas, B. Petracca, et al. (2001)
Blood 97, 63-72
   Abstract »    Full Text »    PDF »
Successful Treatment of Antiepileptic Drug Hypersensitivity Syndrome With Intravenous Immune Globulin.
O. Scheuerman, Y. Nofech-Moses, A. Rachmel, and S. Ashkenazi (2001)
Pediatrics 107, 14e-14
   Abstract »    Full Text »
Toxic Epidermal Necrolysis in Children--An Update.
M. Ringheanu and T. A. Laude (2000)
Clinical Pediatrics 39, 687-694
   Abstract »    PDF »
Life-Threatening Toxic Epidermal Necrolysis with Thalidomide Therapy for Myeloma.
S. V. Rajkumar, M. A. Gertz, and T. E. Witzig (2000)
N. Engl. J. Med. 343, 972-973
   Full Text »
Tissue-Specific Bcl-2 Protein Partners in Apoptosis: An Ovarian Paradigm.
S. Y. Hsu and A. J. W. Hsueh (2000)
Physiol Rev 80, 593-614
   Abstract »    Full Text »    PDF »
Improving the Outcome of Patients With Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome.
R. S. Stern (2000)
Arch Dermatol 136, 410-411
   Full Text »    PDF »
Recent Therapeutic Advances in Dermatology.
G. M. Lipper, K. A. Arndt, and J. S. Dover (2000)
JAMA 283, 175-177
   Full Text »    PDF »
Identification and Characterization of a Ligand-independent Oligomerization Domain in the Extracellular Region of the CD95 Death Receptor.
G. Papoff, P. Hausler, A. Eramo, M. G. Pagano, G. Di Leve, A. Signore, and G. Ruberti (1999)
J. Biol. Chem. 274, 38241-38250
   Abstract »    Full Text »    PDF »
IL-5 Mediates Eosinophilic Rejection of MHC Class II-Disparate Skin Allografts in Mice.
A. Le Moine, M. Surquin, F. X. Demoor, J. C. Noel, M.-A. Nahori, M. Pretolani, V. Flamand, M. Y. Braun, M. Goldman, and D. Abramowicz (1999)
J. Immunol. 163, 3778-3784
   Abstract »    Full Text »    PDF »
Soluble Fas Ligand Induces Epithelial Cell Apoptosis in Humans with Acute Lung Injury (ARDS).
G. Matute-Bello, W. C. Liles, K. P. Steinberg, P. A. Kiener, S. Mongovin, E. Y. Chi, M. Jonas, and T. R. Martin (1999)
J. Immunol. 163, 2217-2225
   Abstract »    Full Text »    PDF »
Cutting Edge: RANTES Regulates Fas Ligand Expression and Killing by HIV-Specific CD8 Cytotoxic T Cells.
F. Hadida, V. Vieillard, L. Mollet, I. Clark-Lewis, M. Baggiolini, and P. Debre (1999)
J. Immunol. 163, 1105-1109
   Abstract »    Full Text »    PDF »
Role of Fas (CD95) in tubulointerstitial disease induced by unilateral ureteric obstruction.
J. Hughes and R. J. Johnson (1999)
Am J Physiol Renal Physiol 277, F26-F32
   Abstract »    Full Text »    PDF »
Dissecting Fas signaling with an altered-specificity death-domain mutant: Requirement of FADD binding for apoptosis but not Jun N-terminal kinase activation.
H. Y. Chang, X. Yang, and D. Baltimore (1999)
PNAS 96, 1252-1256
   Abstract »    Full Text »    PDF »
Treating TEN with Intravenous Immunoglobulin.
(1998)
Journal Watch Dermatology 1998, 1
   Full Text »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)